Papers - Matsumoto, Kazuaki

テイコプラニンにおける血中トラフ濃度20μg/mL以上の臨床的効果、安全性.

髙倉俊二, 竹末芳生, 大曲貴夫, 笠原敬, 関雅文, 高橋佳子, 時松一成, 松元一明, 三鴨廣繁.

日本化学療法学会雑誌 60   501 - 505 2012

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1340-7007

Safety analysis of liposomal amphotericin B in adult patients: anaemia, thrombocytopenia, nephrotoxicity, hepatotoxicity and hypokalaemia.

Shigemi Akari, Matsumoto Kazuaki, Ikawa Kazuro, Yaji Keiko, Shimodozono Yoshihiro, Morikawa Norifumi, Takeda Yasuo, Yamada Katsushi.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS 38 ( 5 ) 417 - 420 2011.11

Research paper (scientific journal), Joint Work, Accepted,  ISSN  0924-8579

• Access to Document (DOI)

An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication.

Kanazawa Naoko, Matsumoto Kazuaki, Ikawa Kazuro, Fukamizu Tomohide, Shigemi Akari, Yaji Keiko, Shimodozono Yoshihiro, Morikawa Norifumi, Takeda Yasuo, Yamada Katsushi.

JOURNAL OF INFECTION AND CHEMOTHERAPY (SPRINGER TOKYO)  17 ( 2 ) 297 - 300 2011.04

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1341-321X

　View Summary

Teicoplanin is a glycopeptide antibacterial agent that has a long serum half-life and therefore takes time to achieve steady-state conditions. An appropriate initial dosing is needed for teicoplanin to promptly reach an effective serum trough concentration. However, little information is available on tailoring the initial dosing for patients with various characteristics. The objective of this study was to develop a nomogram for determining teicoplanin initial dose to promptly reach an effective trough concentration (a parts per thousand yen13 mu g/mL). A logistic regression analysis was performed to test whether the area under the concentration time curve (AUC) is a significant predictor of microbiological response (persistence 0; eradication 1). The study included 24 adult patients with methicillin-resistant Staphylococcus aureus infections [minimal inhibitory concentration (MIC) for the isolates was < 2 mu g/mL). Each AUC was estimated using individual dose, creatinine clearance (CL(cr)), and body weight data. The target value, which gives about a 0.9 microbiological eradication probability, was 750 mu g h/mL for AUC from zero to 24 h (AUC(0-24 h)). Using published population pharmacokinetic parameters, the dose required to achieve the AUC(0-24 h) target was calculated as dose (mg) = 750 x (0.00498 x CL(cr) (mL/min) + 0.00426 x body weight (kg). For various combinations of CL(cr) and body weight, we checked the calculated doses using a therapeutic drug monitoring (TDM)-supporting software and developed a nomogram. The nomogram would be useful for initial dose adjustment to promptly reach an effective serum trough concentration and avoid adverse events of teicoplanin.

• Access to Document (DOI)

Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction.

Matsumoto Kazuaki, Takeshita Ayumi, Ikawa Kazuro, Shigemi Akari, Yaji Keiko, Shimodozono Yoshihiro, Morikawa Norifumi, Takeda Yasuo, Yamada Katsushi.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (ELSEVIER SCIENCE BV)  36 ( 2 ) 179 - 181 2010.08

Research paper (scientific journal), Joint Work, Accepted,  ISSN  0924-8579

　View Summary

The major adverse event associated with linezolid treatment is reversible myelosuppression, mostly thrombocytopenia. Recent studies have reported that the incidence of linezolid-induced thrombocytopenia was higher in patients with renal failure than in patients with normal renal function, although the underlying mechanisms of this toxicity are still unknown. The present study thus aimed to investigate the relationship between renal function and linezolid exposure as well as the effects of drug exposure on thrombocytopenia. A statistically significant (P < 0.01) strong correlation (r = 0.933) was observed between linezolid clearance and creatinine clearance. A negative correlation (r = -0.567) was also shown between linezolid clearance and blood urea nitrogen, although the correlation was not statistically significant. In thrombocytopenic patients, the trough concentration was 14.4-35.6 mg/L and the area under the plasma linezolid concentration-time curve for 24 h (AUC(24 h)) was 513.1-994.6 mg h/L; in non-thrombocytopenic patients, drug exposure was relatively low (6.9 mg/L and 7.2 mg/L for trough concentration and 294.3 mg h/L and 323.6 mg h/L for AUC(24 h)). These results provide a pharmacokinetic explanation for the mechanism of the adverse event that renal dysfunction increased linezolid trough concentration and AUC and that higher drug exposure induced thrombocytopenia. (C) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

• Access to Document (DOI)

Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections.

Matsumoto Kazuaki, Kanazawa Naoko, Ikawa Kazuro, Fukamizu Tomohide, Shigemi Akari, Yaji Keiko, Shimodozono Yoshihiro, Morikawa Norifumi, Takeda Yasuo, Yamada Katsushi.

JOURNAL OF INFECTION AND CHEMOTHERAPY (SPRINGER TOKYO)  16 ( 3 ) 193 - 199 2010.06

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1341-321X

　View Summary

An initial loading procedure has been recommended to enable teicoplanin to promptly reach an effective serum concentration for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). This study aimed to retrospectively evaluate the pharmacokinetics and pharmacodynamics of teicoplanin to determine the therapeutic target for the teicoplanin trough concentration and an appropriate dosing method during the first 3 days. The mean trough concentrations were 13.2 mg/L for patients with eradication of MRSA. Moreover, logistic regression analysis showed that the teicoplanin trough concentration was 13 mg/L to achieve MRSA eradication with a probability of 89.0%. The rates of achieving a parts per thousand yen13 mg/L in a parts per thousand currency sign24, 24-36 and a parts per thousand yen36 mg/kg (total dose during the first 3 days) groups were 9.1, 48.4 and 87.5%, respectively. These results suggest that the administration of a parts per thousand yen36 mg/kg during the first 3 days is appropriate to promptly obtain a trough concentration target of a parts per thousand yen13 mg/L for the initial treatment of MRSA infections.

• Access to Document (DOI)

腎機能障害を有する術後MRSA感染症患者2例におけるリネゾリドの体内動態.

竹下鮎美, 松元一明, 茂見茜里, 猪川和朗, 森川則文, 武田泰生, 山田勝士.

日本外科感染症学会雑誌 7   373 - 376 2010

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1349-5755

Receptor-Mediated Uptake of Human alpha 1-Acid Glycoprotein into Liver Parenchymal Cells in Mice.

Matsumoto Kazuaki, Nishi Koji, Kikuchi Mari, Watanabe Hiroshi, Nakajou Keisuke, Komori Hisakazu, Kadowaki Daisuke, Suenaga Ayaka, Maruyama Toru, Otagiri Masaki.

DRUG METABOLISM AND PHARMACOKINETICS 25 ( 1 ) 101 - 107 2010

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1347-4367

Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa.

Shigemi Akari, Matsumoto Kazuaki, Yaji Keiko, Shimodozono Yoshihiro, Takeda Yasuo, Miyanohara Hiroaki, Kawamura Hideki Orita Michiyo, Tokuda Koichi. Nishi Junichiro, Yamada Katsushi.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (ELSEVIER SCIENCE BV)  34 ( 6 ) 589 - 591 2009.12

Research paper (scientific journal), Joint Work, Accepted,  ISSN  0924-8579

　View Summary

Optimal use of carbapenems is an important issue in the prevention of resistance in Pseudomonas aeruginosa. In this study, we investigated the correlation between antimicrobial use density (AUD) of carbapenems and imipenem/cilastatin (IPM/CS) or meropenem (MEPM) susceptibility of P. aeruginosa strains. The AUD of five carbapenems [IPM/CS, panipenem/betamipron, biapenem, MEPM and doripenem (DRPM)] was examined every 6 months between 2006 and 2008. The AUD was calculated using the defined daily doses methodology developed by the World Health Organisation. A minimum inhibitory concentration of IPM/CS or MEPM of <= 4 mg/L was considered to be sensitive. There was a significant negative correlation between MEPM susceptibility and the total AUD of MEPM and DRPM [r = -0.823, 95% confidence interval (CI) -0.035 to -0.980; P = 0.044]. Furthermore, there was a significant correlation between MEPM susceptibility and IPM/CS susceptibility (r = 0.839, 95% CI 0.084 to 0.981; P = 0.037). Cross-resistance was therefore investigated and only 5.6% of MEPM-insensitive strains were susceptible to IPM/CS, although 43.3% of IPM/CS-insensitive strains were susceptible to MEPM. These results suggest that curtailing the use of MEPM and DRPM may curb the emergence not only of MEPM-resistant strains but also IPM/CS-resistant strains. (C) 2009 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

• Access to Document (DOI)

Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes.

Matsumoto Kazuaki, Ikawa Kazuro, Abematsu Kazuko, Fukunaga Naoko, Nishida Kentaro, Fukamizu Tomohide, Shimodozono Yoshihiro, Morikawa Norifumi, Takeda Yasuo, Yamada Katsushi.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (ELSEVIER SCIENCE BV)  34 ( 1 ) 91 - 94 2009.07

Research paper (scientific journal), Joint Work,  ISSN  0924-8579

　View Summary

Voriconazole metabolism is mostly mediated via the cytochrome P450 (CYP) 2C19 isozyme. The non-wild (mutant) type of CYP2C19 is generally found in 60-70% of Asian populations. Because the voriconazole trough plasma concentration has been reported to correlate with hepatotoxicity, this study investigated the effect of CYP2C19 polymorphism on the relationship between voriconazole trough concentrations and liver function abnormalities in 29 Japanese patients with fungal infections (CYP2C19 wild-type, n = 10; non-wild-type, n = 19). Hepatotoxicity, defined as liver enzyme abnormality according to the National Cancer Institute criteria, was observed in 10 (34.5%) of 29 patients with a trough concentration >= 3.9 mg/L. Logistic regression analysis suggested that the therapeutic range for the voriconazole trough concentration should be 2-4 mg/L. Non-linear pharmacokinetic analysis suggested that voriconazole therapy should be initiated with a dose of 7.2-8.9 mg/kg/day for CYP2C19 wild-type and 4.4-6.5 mg/kg/day for the non-wild-type in Japanese patients. These recommended initial dosages and subsequent dose adjustment for the target concentration range by therapeutic drug monitoring should avoid adverse events and thus enable continued effective voriconazole therapy for Japanese patients with mycoses. (C) 2009 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

• Access to Document (DOI)

Renal function as a predictor of linezolid-induced thrombocytopenia.

Matsumoto Kazuaki, Takeda Yasuo, Takeshita Ayumi, Fukunaga Naoko, Shigemi Akari, Yaji Keiko, Shimodozono Yoshihiro, Yamada Katsushi, Ikawa Kazuro, Morikawa Norifumi.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS 33 ( 1 ) 98 - 99 2009.01

Research paper (scientific journal), Joint Work, Accepted,  ISSN  0924-8579

• Access to Document (DOI)

シクロスポリンおよびタクロリムスのTDM支援ソフトウェアの開発.

金子生, 猪川和朗, 福原慶, 森川則文, 福永直子, 深水知英, 松元一明, 下堂薗権洋, 武田泰生, 山田勝士.

TDM研究 26   52 - 58 2009

Research paper (scientific journal), Joint Work, Accepted

A retrospective study of the relationship between high-dose methotrexate chemotherapy-related toxicity and concomitant drugs: non-steroidal anti-inflammatory drugs and sulfametoxazole.

Shibayama Yoshihiko, Sata Takuya, Furuno Yumiko, Motoya Toshiro, Matsumoto Kazuaki, Fukamizu Tomohide, Fukunaga Naoko, Shimodozono Yoshihiro, Takeda Yasuo, Yamada Katsushi

JOURNAL OF APPLIED THERAPEUTIC RESEARCH 7   11 - 14 2009

Research paper (scientific journal), Joint Work, Accepted

Relationship between methotrexate concentration in serum and half-life of methotrexate in high-dose methotrexate therapy: a retorospective study.

Shibayama Yoshihiko, Motoya Toshiro, Yoshikawa Yoshimi, Matsumoto Kazuaki, Fukamizu Tomohide, Fukunaga Naoko, Shimodozono Yoshihiro, Takeda Yasuo, Yamada, Katsushi.

JOURNAL OF APPLIED THERAPEUTIC RESEARCH 6   25 - 28 2008

Research paper (scientific journal), Joint Work, Accepted

alpha(1)-Acid glycoprotein suppresses rat acute inflammatory paw edema through the inhibition of neutrophils activation and prostaglandin E-2 generation.

Matsumoto Kazuaki, Nishi Koji, Kikuchi Mari, Kadowaki Daisuke, Tokutomi Yoshiko, Tokutomi Naofumi, Nishi Katsuhide, Suenaga Ayaka, Otagiri Masaki.

BIOLOGICAL & PHARMACEUTICAL BULLETIN 30 ( 7 ) 1226 - 1230 2007.07

Research paper (scientific journal), Joint Work, Accepted,  ISSN  0918-6158

A retrospective study of the relationship between methotrexate clearance and hyperuricemia following high-dose methotrexate therapy.

Shibayama Yoshihiko, Yoshikawa Yoshimi, Matsumoto Kazuaki, Shimodozono Yoshihiro, Miyagoe Taeko, Kurita Miho, Kusadome Chie, Yamaguchi Mariko, Nishi Yaeno, Motoya Toshiro, Takeda Yasuo, Yamada Katsushi.

JOURNAL OF APPLIED THERAPEUTIC RESEARCH 6 ( 1 ) 3 - 6 2006

Research paper (scientific journal), Joint Work, Accepted

テイコプラニン維持量設定ノモグラムの作成.

宮越妙子, 松元一明, 大磯茂, 下堂薗権洋, 武田泰生, 山田勝士.

日本病院薬剤師会雑誌 41   1267 - 1270 2005

Research paper (scientific journal), Joint Work, Accepted

Effects of alpha(1)-acid glycoprotein on isometric tension of mouse aorta.

Tokutomi Yoshiko, Okamoto Shigehiro, Matsumoto Kazuaki, Otagiri Masaki, Nishi Katsuhide, Tokutomi Naofumi.

EUROPEAN JOURNAL OF PHARMACOLOGY 477 ( 2 ) 137 - 141 2003.09

Research paper (scientific journal), Joint Work, Accepted,  ISSN  0918-6158

Effect of alpha(1)-acid glycoprotein on erythrocyte deformability and membrane stabilization.

Matsumoto Kazuaki, Nishi Katsuhide, Tokutomi Yoshiko, Irie Tetsumi, Suenaga Ayaka, Otagiri Masaki.

BIOLOGICAL & PHARMACEUTICAL BULLETIN 26 ( 1 ) 123 - 126 2003.01

Research paper (scientific journal), Joint Work, Accepted,  ISSN  0918-6158

α(1)-酸性糖蛋白質の血液循環系に及ぼす作用.

松元一明, 岡本茂洋, 徳冨芳子, 西勝英、丸山徹, 末永綾香, 小田切優樹.

人工血液 11   144 - 150 2003

Research paper (scientific journal), Joint Work, Accepted

Characterization of ligand binding sites on the alpha(1)-acid glycoprotein in humans, bovines and dogs.

Matsumoto Kazuaki, Sukimoto Katsuaki, Nishi Koji, Maruyama Toru, Suenaga Ayaka, Otagiri Masaki.

DRUG METABOLISM AND PHARMACOKINETICS 17 ( 4 ) 300 - 306 2002

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1347-4367